Roundup: Partnership to revolutionise treatment of liver tumours, and more

Health Tech World explores the latest business developments in the world of health technology.

Partnership to revolutionise treatment of liver tumours

Proximie – a health technology platform digitising operating rooms – has announced a partnership with HistoSonics, the manufacturer of the Edison Histotripsy System1 and novel histotripsy therapy platforms used for non-invasive treatment of liver tumours.

Proximie’s OR intelligence platform offers a tailored digital ecosystem and facilitates real-time connectivity; unified data, including data capture, structure, and control capabilities; AI-enabled insight; and a context-rich video library.

Within the partnership, Proximie and HistoSonics will integrate the Proximie platform and the Edison System to hospitals and ambulatory surgery centers across the US.

Specifically, Proximie’s real-time connectivity capabilities will enable HistoSonics’ medical directors and physician faculty to share live expertise to surgeons using the Edison System; treating patients’ liver tumours more effectively via focused ultrasound sonic beam therapy, while adding new levels of rapidity to HistoSonic’s diagnostics and operations.

Initial regions for the partnership include Chicago, Colorado, Florida, Louisiana, Seattle, and Southern California.

Partnership to accelerate respiratory disease research through AI-powered clinical registries

AI research company, Century Health, and tech-driven pulmonary care provider, Nimbus Health, have entered into a partnership to develop high-quality, real-world datasets for serious respiratory diseases.

The initial focus will be on chronic obstructive pulmonary disease (COPD) and asthma, with the potential to expand into other areas where innovation in treatment can significantly impact patient outcomes.

Through this collaboration, Century Health’s AI-driven platform will integrate with Nimbus Health’s EHR system to curate and enrich clinical registries.

These datasets will enable insights into the complex relationships between patient profiles, disease progression, and treatment outcomes.

Historically, much of this data has been buried in unstructured clinical notes and reports, making it difficult to extract and analyze, even for dedicated research teams.

For pharmaceutical companies, analyses conducted on the datasets can help address complex real-world evidence (RWE) research needs, including treatment patterns, adherence, exacerbation rates, and comparative effectiveness studies.

Real-world studies are critical to understanding the effectiveness of interventions in clinical practice as a complement to highly controlled evidence from clinical trials.

The partnership will leverage Century Health’s AI-powered data platform to transform de-identified clinical data from Nimbus Health’s network into rich, continuously-refreshed, research-ready registries.

Century Health will unlock structured insights at scale to drive better understanding of COPD and asthma in real-world settings and accelerate the development of new therapies.

CDX Medical Technologies secures US$2.5m

CDX Medical Technologies (CDX), a membrane oxygenation (ECMO) pump innovation company, has raised US$2.5m in its Series A funding round.

The round was led by Joe Kiani, Founder of Masimo and a world-renowned health technology entrepreneur, with participation from leading industry executives and the CDX Board of Directors.

Kiani, who also founded Willow Laboratories and co-founded Like Minded Labs, will join the CDX Board.

Following extensive bench and in vivo testing, the company is preparing to submit its proprietary pump for regulatory approval for use in ECMO. The new funding will support completion of submission testing, early commercial development and team expansion.

Omega Healthcare expands collaboration with Microsoft to accelerate AI capabilities

Tech-enabled RCM service provider, Omega Healthcare, has expanded its collaboration with Microsoft to further enhance its advanced AI capabilities.

Through the integration of Microsoft Azure AI models through Azure AI Foundry, and the company’s proprietary Omega Digital Platform (ODP), Omega Healthcare launched more than 20 generative and agentic AI solutions to help healthcare organisations enhance revenue cycle operations and improve financial performance.

The AI solutions incorporate Microsoft Azure’s intelligent automation engines that are integrated across the ODP, supporting the full revenue cycle: patient access, mid-cycle operations, and back-end processes.

These modules combine advanced AI models in Azure AI Foundry with Omega Healthcare’s deep domain expertise to automate routine processes, such as medical coding and integrate with ODP’s AI/ML models to support key services for customers, such as clinical documentation improvement (CDI), denials management and prevention.

Lifeforce and Toku combine AI Retinal Scans with the world’s largest longevity-medicine platform

The world’s largest longevity medicine platform, Lifeforce, and Toku, a health technology company using AI to translate a single retinal image into real-time biological age and cardiovascular risk scores, have announced a nationwide partnership.

The collaboration will turn thousands of routine eye exams each week into powerful opportunities for early health insights and proactive intervention.

The partnership integrates Toku’s BioAge wellness product with its forthcoming CLAiR technology which has received FDA Breakthrough Device designation.

CLAiR is currently in development, with anticipated FDA approval in 2026, and aims to transform non-invasive cardiovascular risk assessment using retinal imaging and AI.

Through this collaboration, individuals who complete a BioAge analysis – comparing their biological age to their chronological age using a retinal image – will be connected to Lifeforce’s comprehensive longevity platform.

Lifeforce offers at-home diagnostics, board-certified longevity physicians, personalised protocols, and certified health coaches, enabling participants to take data-driven steps toward extending their healthspan.

Revealing critical care gaps for patients with rare genetic condition

Health technology company PicnicHealth has announced its research collaboration with Neurocrine Biosciences – the CAHtalog Registry.

The research has identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth’s AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing – the current standard treatment – to maintain condition control.

CAHtalog was founded in 2021 by PicnicHealth and Neurocrine, in collaboration with the CARES Foundation, to establish a U.S.-based registry that helps patients with CAH by advancing patient-centered research and enhancing the scientific community’s foundational knowledge of the condition.

CAH is a rare genetic condition that affects adrenal gland function, disrupting hormone production and impacting growth and development.

Conducting longitudinal studies on rare diseases is challenging for researchers using site-based models due to the wide geographic spread of patients. Tech-enabled research models improve access and participation by removing the burden of in-person visits over extended periods.

PicnicHealth conducts non-interventional research by collecting medical records from anywhere patients receive care and enabling patients to complete research activities through an intuitive app.

The app also features an AI assistant that empowers patients to navigate their medical records with ease.

This novel approach to registries helps life sciences companies answer their research questions more efficiently while fostering long-term patient engagement.

The CARES Foundation proved crucial for successfully recruiting and engaging CAH patients in the study.